Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This appointment brings a further focus to linking rheumatology discovery science and clinical trials in NDORMS, strengthening translational rheumatology research across the department to deliver transformative treatments for patients with inflammatory arthritis.

Professor Adam Croft

Adam joins NDORMS at the University of Oxford on January 1st 2027, from the University of Birmingham, where he is Professor of Translational Rheumatology, Head of the Department of Inflammation and Ageing, Versus Arthritis Chair of Rheumatology and Director of the new £50 million MRC CoRE in Restorative Immunology. His research focuses on understanding the mechanisms that drive inflammation and the development of new treatments for patients with autoimmune rheumatic and chronic inflammatory diseases.  He is particularly known for his work on the role of fibroblasts in inflammatory arthritis and the development of therapies that target these cells. Alongside his research, Adam is a practising rheumatologist with clinical expertise in early and treatment-resistant inflammatory arthritis.

As Norman Collisson Professor, Adam will provide leadership in academic rheumatology, with a particular focus on translational research and inflammatory arthritis. He will work across the University and NHS to strengthen Oxford’s translational rheumatology research programme and develop collaborations within NDORMS, the wider Medical Sciences Division and with national and international partners. 

A key part of the role will be translating new discoveries into early phase and late phase trials by working across the Botnar and Kennedy Institutes. Adam will also be working in the Oxford University Hospitals NHS Foundation Trust to support the early inflammatory arthritis service. 

Professor Jonathan Rees, Head of NDORMS and Director of the Botnar Institute for Musculoskeletal Sciences, said: ‘I am delighted to welcome Adam to the department. This is a key strategic appointment for NDORMS, the University and rheumatology healthcare nationally. Adam brings significant expertise and leadership as highlighted by the recent launch of the new MRC CoRE in Restorative Immunology for which he is the Director. His appointment coupled with the existing expertise and resources available in our Institutes will provide him the opportunity to make a major patient and societal impact in the future. I am so pleased he has agreed to join our NDORMS team.’

Adam said: ‘I'm honoured to take up the Norman Collison Professorship at such a pivotal moment for rheumatology research. Advances in precision medicine, biomarkers, artificial intelligence and targeted therapies mean we are now moving beyond simply managing disease towards earlier diagnosis, personalised treatment, disease prevention and, ultimately, the possibility of cure. This position provides a unique platform to translate these scientific advances into real-world benefit for patients, supported by the world-leading discovery, experimental medicine and clinical trials infrastructure here in Oxford. I look forward to building on the legacy of this role and to continuing close collaboration with colleagues across NDORMS and the Kennedy Institute to deliver transformative impact for our patients.’

Established in 2001 through an endowment from the late Norman Collisson, the Norman Collisson Professorship is a statutory chair based within NDORMS and associated with St Peter’s College. The post provides an outstanding platform for leading and developing clinical academic rheumatology in Oxford.

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.